Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
24
GCTK Quote, Financials, Valuation and Earnings
Last price:
$0.68
Seasonality move
:
-7.58%
Day range:
$0.68 - $0.78
52-week range:
$0.62 - $15.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.72x
P/B ratio:
0.20x
Volume:
203.5K
Avg. volume:
1.3M
1-year change:
-92.35%
Market cap:
$568K
Revenue:
--
EPS (TTM):
-$1,319.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
-- | -- | -- | -- | -- |
|
ABT
Abbott Laboratories
|
$11B | $1.15 | 13.48% | 31.15% | $132.12 |
|
ARAY
Accuray, Inc.
|
$111.9M | -$0.05 | -1.19% | -296.83% | $2.53 |
|
ATEC
Alphatec Holdings, Inc.
|
$196.6M | -$0.00 | 16.23% | -99.65% | $24.42 |
|
BSX
Boston Scientific Corp.
|
$5.2B | $0.79 | 9.79% | 62% | $100.09 |
|
PSTV
Plus Therapeutics, Inc.
|
$974K | -$0.84 | -8.03% | -97.28% | $140.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
$0.68 | -- | $568K | -- | $0.00 | 0% | 6.72x |
|
ABT
Abbott Laboratories
|
$101.83 | $132.12 | $176.1B | 27.26x | $0.63 | 2.37% | 4.00x |
|
ARAY
Accuray, Inc.
|
$0.38 | $2.53 | $40.1M | 149.00x | $0.00 | 0% | 0.09x |
|
ATEC
Alphatec Holdings, Inc.
|
$11.03 | $24.42 | $1.7B | -- | $0.00 | 0% | 2.18x |
|
BSX
Boston Scientific Corp.
|
$61.86 | $100.09 | $90.7B | 31.53x | $0.00 | 0% | 4.55x |
|
PSTV
Plus Therapeutics, Inc.
|
$2.92 | $140.50 | $17.5M | -- | $0.00 | 0% | 2.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
54.52% | 3.743 | 1.75% | 1.49x |
|
ABT
Abbott Laboratories
|
21.33% | 0.736 | 6.98% | 1.05x |
|
ARAY
Accuray, Inc.
|
76.53% | 3.369 | 177.87% | 0.52x |
|
ATEC
Alphatec Holdings, Inc.
|
94.3% | 1.812 | 18.94% | 1.24x |
|
BSX
Boston Scientific Corp.
|
33.07% | 1.671 | 8.45% | 0.94x |
|
PSTV
Plus Therapeutics, Inc.
|
17.04% | 1.919 | 1.16% | 1.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
-$9K | -$4.3M | -2079.63% | -- | -- | -$4.7M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | -$21.6M |
|
ATEC
Alphatec Holdings, Inc.
|
$130.4M | -$5.4M | -23.65% | -1092.5% | -2.52% | $5.7M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$5.7M | -- | -- | -420.04% | -$6.3M |
GlucoTrack, Inc. vs. Competitors
-
Which has Higher Returns GCTK or ABT?
Abbott Laboratories has a net margin of -- compared to GlucoTrack, Inc.'s net margin of 15.71%. GlucoTrack, Inc.'s return on equity of -- beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About GCTK or ABT?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Abbott Laboratories has an analysts' consensus of $132.12 which suggests that it could grow by 29.75%. Given that Abbott Laboratories has higher upside potential than GlucoTrack, Inc., analysts believe Abbott Laboratories is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 ABTAbbott Laboratories16 7 0 -
Is GCTK or ABT More Risky?
GlucoTrack, Inc. has a beta of 0.613, which suggesting that the stock is 38.714% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.251%.
-
Which is a Better Dividend Stock GCTK or ABT?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.37% to investors and pays a quarterly dividend of $0.63 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GCTK or ABT?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. GlucoTrack, Inc.'s net income of -$4.2M is lower than Abbott Laboratories's net income of $1.8B. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 27.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 4.00x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M ABTAbbott Laboratories4.00x 27.26x $11.5B $1.8B
-
Which has Higher Returns GCTK or ARAY?
Accuray, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -13.47%. GlucoTrack, Inc.'s return on equity of -- beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About GCTK or ARAY?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 571.72%. Given that Accuray, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Accuray, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 ARAYAccuray, Inc.2 0 0 -
Is GCTK or ARAY More Risky?
GlucoTrack, Inc. has a beta of 0.613, which suggesting that the stock is 38.714% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.317, suggesting its more volatile than the S&P 500 by 31.653%.
-
Which is a Better Dividend Stock GCTK or ARAY?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or ARAY?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. GlucoTrack, Inc.'s net income of -$4.2M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 0.09x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M ARAYAccuray, Inc.0.09x 149.00x $102.2M -$13.8M
-
Which has Higher Returns GCTK or ATEC?
Alphatec Holdings, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -10.21%. GlucoTrack, Inc.'s return on equity of -- beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M ATECAlphatec Holdings, Inc.61.24% -$0.14 $632.1M -
What do Analysts Say About GCTK or ATEC?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.42 which suggests that it could grow by 121.37%. Given that Alphatec Holdings, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Alphatec Holdings, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 ATECAlphatec Holdings, Inc.8 0 0 -
Is GCTK or ATEC More Risky?
GlucoTrack, Inc. has a beta of 0.613, which suggesting that the stock is 38.714% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.117, suggesting its more volatile than the S&P 500 by 11.658%.
-
Which is a Better Dividend Stock GCTK or ATEC?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or ATEC?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. GlucoTrack, Inc.'s net income of -$4.2M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 2.18x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M ATECAlphatec Holdings, Inc.2.18x -- $212.9M -$21.7M
-
Which has Higher Returns GCTK or BSX?
Boston Scientific Corp. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of 12.68%. GlucoTrack, Inc.'s return on equity of -- beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About GCTK or BSX?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Boston Scientific Corp. has an analysts' consensus of $100.09 which suggests that it could grow by 62.16%. Given that Boston Scientific Corp. has higher upside potential than GlucoTrack, Inc., analysts believe Boston Scientific Corp. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 BSXBoston Scientific Corp.24 0 0 -
Is GCTK or BSX More Risky?
GlucoTrack, Inc. has a beta of 0.613, which suggesting that the stock is 38.714% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.926%.
-
Which is a Better Dividend Stock GCTK or BSX?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or BSX?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. GlucoTrack, Inc.'s net income of -$4.2M is lower than Boston Scientific Corp.'s net income of $670M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 31.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 4.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M BSXBoston Scientific Corp.4.55x 31.53x $5.3B $670M
-
Which has Higher Returns GCTK or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -417.92%. GlucoTrack, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M PSTVPlus Therapeutics, Inc.93.27% -$0.04 $4.8M -
What do Analysts Say About GCTK or PSTV?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $140.50 which suggests that it could grow by 4711.64%. Given that Plus Therapeutics, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 PSTVPlus Therapeutics, Inc.3 1 0 -
Is GCTK or PSTV More Risky?
GlucoTrack, Inc. has a beta of 0.613, which suggesting that the stock is 38.714% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.
-
Which is a Better Dividend Stock GCTK or PSTV?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or PSTV?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. GlucoTrack, Inc.'s net income of -$4.2M is higher than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 2.30x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M PSTVPlus Therapeutics, Inc.2.30x -- $1.4M -$5.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
42
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Buy
51
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
75
CAR alert for Apr 8
Avis Budget Group, Inc. [CAR] is up 2.34% over the past day.
Buy
100
BETR alert for Apr 8
Better Home & Finance Holding Co. [BETR] is down 21.92% over the past day.
Sell
40
ELVN alert for Apr 8
Enliven Therapeutics, Inc. [ELVN] is down 0.51% over the past day.
